Clinical Takeaway Clinical Takeaway: GLP-1 receptor agonists show no consistent causal relationship with improvement or worsening of common mental illnesses based on genetic analysis, suggesting that observed mental health changes in patients...
Endocannabinoid System Clinical Research Guide
Clinical Takeaway GLP-1 receptor agonists show no clear causal relationship with reduced risk of major mental illnesses including depression, anxiety, bipolar disorder, and schizophrenia based on genetic analysis. Current evidence does not...
Endocannabinoid System & GLP-1 Receptor Mental Health Research
Clinical Takeaway GLP-1 receptor agonists, the drug class that includes medications like semaglutide, were studied for their potential causal effects on ten common mental health conditions using genetic analysis methods that reduce...
Large Study Finds No Evidence Cannabis Use Accelerates Cognitive Decline or Raises Dementia Risk in Older Adults
Cannabis use was not linked to longitudinal cognitive decline or dementia risk. Within the limits of these cohorts, we found no evidence that cannabis use contributes substantially to cognitive ageing or dementia risk in older adults.
Endocannabinoid System & GLP-1 Receptor Mental Health Evidence
Clinical Takeaway GLP-1 receptor agonists, the drug class that includes medications like semaglutide, were studied for their potential causal effects on ten common mental health conditions using genetic analysis data. The findings...
Endocannabinoid System & GLP-1 Mental Health Evidence
Clinical Takeaway GLP-1 receptor agonists, the drug class that includes medications like semaglutide, were studied using genetic analysis to assess their causal effect on ten psychiatric conditions. The findings suggest these medications...